- Verona Pharma reported positive trial results for the use of its ensifentrine treatment for chronic obstructive pulmonary disease.

The second-phase trial, involving use of a dry powder inhaler, had met its primary endpoint of a highly statistically significant and clinically meaningful dose-dependent improvement in lung function.

Secondary lung function endpoints were also met, with data supportive of twice daily dosing.

'These very promising data with the dry powder inhaler (DPI) formulation support our view that ensifentrine is an effective bronchodilator in COPD patients, whether administered as a dry powder via a handheld inhaler or as a suspension via a nebulizer,' chief executive Jan-Anders Karlsson said.

'Our proof-of-concept dry powder formulation can be adapted to different DPI devices used in the market.'

'Millions of patients prefer to use a handheld device, and these data significantly expand ensifentrine's commercial potential.'

'We plan to complete further development and commercialization of the DPI formulation with a partner and these clinical data strongly support this opportunity.'

At 9:57am: [LON:VRP] Verona Pharma PLC share price was 0p at 42.3p

Story provided by